4DMedical is a global medical technology company that has created a step change in the capacity to understand the lung function of patients with respiratory diseases accurately and quickly.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®)—the first modality to dynamically quantify ventilation throughout the lungs—and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS and CT LVAS reports are prepared using 4DMedical’s Software as a Service delivery model using existing clinical imaging equipment or the Company’s revolutionary XV Scanner.

In 2023 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients.